Ginsenoside Rg3 attenuates endometriosis by inhibiting the viability of human ectopic endometrial stromal cells through the nuclear factor-kappaB signaling pathway

Huang, Rui; Chen, Shaohui; Zhao, Min; Li, Zhaoai; Zhu, Lei

doi:10.1016/j.jogoh.2019.101642

Cited by 15 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The activity of Bay11‐7085 has been shown in in vitro studies, but there has been no clinical study of its therapeutic potential. Ginsenoside Rg3, genistein, and curcumin are found in natural products, and they enhanced apoptosis via regulation of the NF‐κB pathway 79,85 . In addition, ginsenoside Rg3 neutralized the effect of TNF‐α to regulate proliferation 79 .…”

Section: Potential New Pharmaceuticals and Their Target‐signaling Pathwaysmentioning

confidence: 99%

“…Ginsenoside Rg3, genistein, and curcumin are found in natural products, and they enhanced apoptosis via regulation of the NF‐κB pathway 79,85 . In addition, ginsenoside Rg3 neutralized the effect of TNF‐α to regulate proliferation 79 . Genistein had a similar capability as a GnRH agonist, that is, inhibiting transforming growth factor (TGF)‐β to regulate NF‐κB.…”

Section: Potential New Pharmaceuticals and Their Target‐signaling Pathwaysmentioning

confidence: 99%

“…Toxicity of high dose is minimal, so it needs more study to test the safe range 314 . Ginsenoside RG3, extracted from ginseng, restored TNF‐α‐induced effects by inhibiting NF‐κB, VEGF, and CASP‐3 in EM, which are responsible for cell proliferation, apoptosis, and angiogenesis 79 . Ginsenoside PPD regulated ERα and PRα expression to suppress autophagy and lesion growth in EM 103 .…”

Section: Potential Pharmaceuticals With Multiple Targetsmentioning

confidence: 99%

See 2 more Smart Citations

Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review

Hung

Zhang

Tan

et al. 2021

Medicinal Research Reviews

View full text Add to dashboard Cite

Endometriosis (EM) is defined as endometrial tissues found outside the uterus. Growth and development of endometriotic cells in ectopic sites can be promoted via multiple pathways, including MAPK/MEK/ERK, PI3K/Akt/mTOR, NF‐κB, Rho/ROCK, reactive oxidative stress, tumor necrosis factor, transforming growth factor‐β, Wnt/β‐catenin, vascular endothelial growth factor, estrogen, and cytokines. The underlying pathophysiological mechanisms include proliferation, apoptosis, autophagy, migration, invasion, fibrosis, angiogenesis, oxidative stress, inflammation, and immune escape. Current medical treatments for EM are mainly hormonal and symptomatic, and thus the development of new, effective, and safe pharmaceuticals targeting specific molecular and signaling pathways is needed. Here, we systematically reviewed the literature focused on pharmaceuticals that specifically target the molecular and signaling pathways involved in the pathophysiology of EM. Potential drug targets, their upstream and downstream molecules with key aberrant signaling, and the regulatory mechanisms promoting the growth and development of endometriotic cells and tissues were discussed. Hormonal pharmaceuticals, including melatonin, exerts proapoptotic via regulating matrix metallopeptidase activity while nonhormonal pharmaceutical sorafenib exerts antiproliferative effect via MAPK/ERK pathway and antiangiogenesis activity via VEGF/VEGFR pathway. N‐acetyl cysteine, curcumin, and ginsenoside exert antioxidant and anti‐inflammatory effects via radical scavenging activity. Natural products have high efficacy with minimal side effects; for example, resveratrol and epigallocatechin gallate have multiple targets and provide synergistic efficacy to resolve the complexity of the pathophysiology of EM, showing promising efficacy in treating EM. Although new medical treatments are currently being developed, more detailed pharmacological studies and large sample size clinical trials are needed to confirm the efficacy and safety of these treatments in the near future.

show abstract

Section: Potential New Pharmaceuticals and Their Target‐signaling Pathwaysmentioning

confidence: 99%

Section: Potential New Pharmaceuticals and Their Target‐signaling Pathwaysmentioning

confidence: 99%

Section: Potential Pharmaceuticals With Multiple Targetsmentioning

confidence: 99%

See 1 more Smart Citation

Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review

Hung

Zhang

Tan

et al. 2021

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…hESCs isolated from patients with endometriosis [16,91] Parthenolide Reduces lesion size and growth of endometriosis-like lesions via suppressing TNFα/NF-κB pathway.…”

Section: Preclinical Drugs For Blocking Nf-κb Signaling In Endometriosismentioning

confidence: 99%

An Update on the Multifaceted Role of NF-kappaB in Endometriosis

2022

View full text Add to dashboard Cite

Endometriosis remains a common but challenging gynecological disease among reproductive-aged women with an unclear pathogenesis and limited therapeutic options. Numerous pieces of evidence suggest that NF-κB signaling, a major regulator of inflammatory responses, is overactive in endometriotic lesions and contributes to the onset, progression, and recurrence of endometriosis. Several factors, such as estrogen, progesterone, oxidative stress, and noncoding RNAs, can regulate NF-κB signaling in endometriosis. In the present review, we discuss the mechanisms by which these factors regulate NF-κB during endometriosis progression and provide an update on the role of NF-κB in affecting endometriotic cells, peritoneal macrophages (PMs) as well as endometriosis-related symptoms, such as pain and infertility. Furthermore, the preclinical drugs for blocking NF-κB signaling in endometriosis are summarized, including plant-derived medicines, NF-κB inhibitors, other known drugs, and the potential anti-NF-κB drugs predicted through the Drug-Gene Interaction Database. The present review discusses most of the studies concerning the multifaceted role of NF-κB signaling in endometriosis and provides a summary of NF-κB-targeted treatment in detail.

show abstract

“…Ginsenoside Rg3, one of the components of KRG, has previously been demonstrated to suppress the growth of endometriosis lesions in rats, to reduce the volume of ectopic lesions, to inhibit expression of the vascular endothelial growth factor (VEGF), and to inhibit angiogenesis [ 32 ]. In addition, ginsenoside Rg3 has been shown to suppress endometriosis by regulating apoptosis and angiogenesis through NF-κB signaling in human ectopic endometrial stromal cells [ 33 ]. PPD can also attenuate the growth of ectopic lesions and eventually suppress the development of endometriosis [ 34 ].…”

Section: Introductionmentioning

confidence: 99%

Korean Red Ginseng attenuates Di-(2-ethylhexyl) phthalate-induced inflammatory response in endometrial cancer cells and an endometriosis mouse model

Song

Won

Lee

et al. 2022

Journal of Ginseng Research

View full text Add to dashboard Cite

Ginsenoside Rg3 attenuates endometriosis by inhibiting the viability of human ectopic endometrial stromal cells through the nuclear factor-kappaB signaling pathway

Cited by 15 publications

References 18 publications

Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review

Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: A review

An Update on the Multifaceted Role of NF-kappaB in Endometriosis

Korean Red Ginseng attenuates Di-(2-ethylhexyl) phthalate-induced inflammatory response in endometrial cancer cells and an endometriosis mouse model

Contact Info

Product

Resources

About